SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-279598
Filing Date
2022-11-08
Accepted
2022-11-08 06:09:33
Documents
13
Period of Report
2022-11-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d396021d8k.htm   iXBRL 8-K 24233
  Complete submission text file 0001193125-22-279598.txt   183244

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atai-20221102.xsd EX-101.SCH 3211
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atai-20221102_def.xml EX-101.DEF 14156
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20221102_lab.xml EX-101.LAB 23296
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20221102_pre.xml EX-101.PRE 15074
7 EXTRACTED XBRL INSTANCE DOCUMENT d396021d8k_htm.xml XML 5085
Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 (617) 699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 221367099
SIC: 2834 Pharmaceutical Preparations